PT Kalbe Genexine Biologics
https://www.kalbe.co.id
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PT Kalbe Genexine Biologics
Asia Deal Watch: Daiichi Sankyo Obtains Brazilian Rights To Mitsubishi Tanabe’s ALS Drug
Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.
Start-Up Quarterly Statistics, Q4 2015
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
China Biobetter EPO Deal Seen Boosting Genexine’s Prospects
Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.
Deals Shaping The Medical Industry, November 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- KG Bio
- PT Kalbe Farma Tbk